Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up

Abstract

Patients with nephropathic cystinosis are required to take 6-hourly immediate-release cysteamine (Cystagon®) to reduce disease progression. This arduous regimen affects quality of life, disrupts sleep, and may result in non-compliance with therapy. Enteric-coated cysteamine bitartrate (EC-cysteamine) was developed as a “proof-of-concept” formulation for twice-daily ingestion. Previous reports have shown this therapy to be effective up to a mean of 14 months. Two subjects (aged 13 and 15 years) received EC-cysteamine for 5–6 years at 60–65 % of their previous total daily dose of immediate-release cysteamine given at 6-h intervals. White blood cell (WBC) cystine levels were monitored every 1–3 months. The administration of EC-cysteamine did not result in any change in mean trough WBC cystine levels or any deterioration in the estimated glomerular filtration rate, thyroid, or liver function, suggesting that delayed-release, twice-daily EC-cysteamine is an effective long-term treatment alternative to immediate-release cysteamine given at 6-h intervals.

DOI: 10.1007/s00467-012-2315-5

2 Figures and Tables

Statistics

050020132014201520162017
Citations per Year

529 Citations

Semantic Scholar estimates that this publication has 529 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Dohil2012TreatmentOC, title={Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up}, author={Ranjan Dohil and Betty L. Cabrera}, journal={Pediatric Nephrology}, year={2012}, volume={28}, pages={507-510} }